Neumora Therapeutics, Inc. (NMRA) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neumora Therapeutics, Inc. on November 21, 2025, covering events occurring on November 17, 2025. The company is a Delaware corporation with its principal executive offices in Watertown, Massachusetts, and its common stock trades on The Nasdaq Global Select Market under the symbol NMRA.
Key Financial Metrics and Transaction Details
The filing details a specific unregistered sale of equity securities resulting from a debt conversion:
- Transaction Type: Conversion of term loan principal into common stock.
- Principal Converted: $2.5 million.
- Conversion Price: $0.8774 per share.
- Shares Issued: 2,849,327 shares of common stock.
- Counterparty: K2 HealthVentures Equity Trust LLC (acting on behalf of K2 HealthVentures LLC).
- Issuance Date: November 20, 2025.
- Regulatory Basis: Issued in reliance on the Section 4(a)(2) exemption of the Securities Act of 1933.
The filing does not provide comprehensive financial statements, including revenue, profit, cash flow, margins, total debt, or liquidity metrics for the reporting period.
Material Changes
The material change reported is the reduction of outstanding term loan principal by $2.5 million and the corresponding increase in outstanding common stock by 2,849,327 shares. This action was executed pursuant to a Loan and Security Agreement entered into on May 9, 2025, and amended on November 4, 2025, which grants the lender the right to convert up to $12.5 million of principal into equity.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the unregistered sale of securities. The document does not disclose any unusual items or contingencies other than the execution of the pre-existing loan conversion terms.
Key Facts for Investor Verification
- Verify the total remaining principal balance of the K2 HealthVentures term loan following the $2.5 million conversion.
- Confirm the total number of outstanding shares of common stock post-issuance to assess dilution impact.
- Review the full terms of the Loan and Security Agreement (May 9, 2025) and its First Amendment (November 4, 2025) to understand remaining conversion rights and interest obligations.
- Check subsequent filings for any additional conversion notices, as the lender retains the right to convert up to $10 million more of the principal.